News Archives - Page 14 of 199

TuesdaySep 23, 2025 11:05 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, previously served as acting chairman of the White House Council of Economic Advisers and has advised FDA, CMS, and major healthcare initiatives. He currently serves as Managing Partner of MEDA Ventures and on several corporate boards. Soligenix CEO Christopher J. Schaber, PhD, said Philipson’s expertise and relationships will be instrumental as the company advances…

TuesdaySep 23, 2025 10:18 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Engages PCAOB Auditor to Support Planned OTCQB Uplist

Fifty 1 Labs (OTC: FITY), a Nevada-based holding company focused on AI-driven drug repurposing and functional medicine, announced it has signed a letter of engagement with a Public Company Accounting Oversight Board registered auditing firm to conduct audits of its 2024 and 2025 financial statements. The audits mark a key step in the company’s plan to uplist to the OTCQB Venture Market, which requires strict reporting and governance standards. CEO Paul Arora said the engagement underscores Fifty 1 Labs’ commitment to transparency and corporate governance, while laying the groundwork to strengthen investor confidence as it advances biotech and wellness initiatives.…

MondaySep 22, 2025 9:30 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) CEO Featured on IBN’s BioMedWire Podcast

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, is featured in the latest episode of IBN’s BioMedWire Podcast. Chairman and CEO Dr. Vuong Trieu discussed the company’s mission to treat cancer and rare diseases, emphasizing Oncotelic’s expertise in tumor microenvironments, regulatory pathways, and intellectual property strategies. He noted that investors should watch for multiple clinical and regulatory milestones over the next 12 months, including IND approvals, expanded indications, and partnership announcements. To view the full press release, visit https://ibn.fm/QbKCl About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development…

MondaySep 22, 2025 9:10 am

BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) First-of-Its-Kind Cable-Free ECG Offers Multi-Angle Signal Capture

As clinicians increasingly recognize the value of accurate at-home electrocardiogram (“ECG”) capture, HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation. The company’s FDA-cleared HeartBeam System is the first cable-free ECG device that captures the heart’s signals from three distinct directions and is designed to be a groundbreaking solution for at-home detection and monitoring of arrhythmias. “HeartBeam’s proprietary system allows for high-fidelity measurements without the complexity of conventional equipment. Unlike standard devices that capture electrical signals from limited perspectives, HeartBeam’s patented approach records from three distinct angles, enabling a more complete view of the heart’s electrical activity. This…

FridaySep 19, 2025 11:00 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical need. The company’s SGX942 is a novel therapeutic aimed at alleviating oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment. “Severe oral mucositis (‘SOM’) often necessitates hospitalization, opioid pain management and feeding tube placement, lowering quality of life substantially. Because of these risks, effective treatment or prevention is critical to ensuring cancer therapies remain on schedule and patients maintain nutrition and comfort,” reads a recent article. In response, the company is advancing a promising candidate,…

FridaySep 19, 2025 9:50 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Closes $375,000 Private Placement

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based products for more accurate breast cancer screening, diagnosis and treatment, announced it has closed a non-brokered private placement of 1.5 million units at $0.25 per unit for gross proceeds of $375,000. Each unit includes one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. An insider acquired 100,000 units under exemptions from MI 61-101 requirements, and the company paid $3,500 and issued 14,000 broker warrants exercisable at $0.25 for three years in connection with the offering.…

FridaySep 19, 2025 9:40 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth.” The release highlights the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy and nanomedicine. Dr. Trieu previously developed Abraxane(R), a nanotechnology-based formulation that transformed treatment for breast, lung and pancreatic cancers, and advanced Cynviloq(TM), a novel micellar paclitaxel therapy. The feature underscores how his track record and expertise position Oncotelic to advance pioneering therapies with strong market potential. To view…

ThursdaySep 18, 2025 9:45 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research

Oncotelic Therapeutics (OTCQB: OTLC) today announced its placement in an editorial published by NetworkNewsWire (“NNW”) titled “Advancing Cancer Research Brings New Hope for Patients Worldwide.” The article highlights the urgent need for innovation in treating deadly cancers such as glioblastoma and pancreatic cancer, as well as rare pediatric disorders. Under the leadership of chair and CEO Dr. Vuong Trieu, Oncotelic is leveraging AI, nanomedicine and advanced clinical strategies to build a transformative pipeline. Backed by an intellectual property portfolio that includes approximately 500 patent applications and 75 granted patents, the company aims to reshape treatment approaches for cancer and rare…

ThursdaySep 18, 2025 9:15 am

BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. The company recently “completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (‘NSCLC’) patients,” reads a recent article. “Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence,” Lantern Pharma CEO and President Panna Sharma was quoted as saying. “This achievement builds…

TuesdaySep 16, 2025 10:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints, showing a favorable safety and pharmacokinetic profile with early signs of antitumor activity. The open-label study in 63 patients with advanced relapsed or refractory solid tumors, including GBM, demonstrated disease control in 48% of evaluable patients at therapeutic dose levels, with notable responses in DDR-deficient cancers such as NSCLC, colon cancer, thymic carcinoma, and GIST. No dose-limiting toxicities were observed, and adverse events were predominantly mild. Lantern plans to advance LP-184 into Phase 1b…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Breaks Categories: News

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Engages PCAOB Auditor to Support Planned OTCQB Uplist

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) CEO Featured on IBN’s BioMedWire Podcast

BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) First-of-Its-Kind Cable-Free ECG Offers Multi-Angle Signal Capture

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Closes $375,000 Private Placement

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research

BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search